Branched-chain amino acid catabolic pathway

The **branched-chain amino acid catabolic pathway** refers to the enzymatic system responsible for the breakdown of the essential amino acids leucine, isoleucine, and valine. Catabolism begins with transamination (via branched-chain aminotransferase, BCAT), producing branched-chain α-keto acids, followed by irreversible oxidative decarboxylation (via branched-chain α-keto acid dehydrogenase complex, BCKDH), yielding acyl-CoA derivatives that enter separate metabolic fates. Proper regulation of this pathway is crucial for energy homeostasis, muscle growth, and modulation of glucose and lipid metabolism. Disruption of BCAA catabolism is implicated in several metabolic diseases, including type 2 diabetes, obesity, fatty liver disease, and the rare maple syrup urine disease. The pathway as a whole is not a drug target, but specific enzymes within the pathway (notably BCKDH) are considered therapeutic targets for conditions like MSUD or metabolic disorders[1][3][4]. Important note: "Branched-chain amino acid pathways" does not refer to a single molecule, receptor, or canonical drug target, but rather to a broad metabolic pathway encompassing several specific enzyme targets. For drug discovery or structured databases, individual enzymes such as branched-chain α-keto acid dehydrogenase complex (BCKDH) or branched-chain aminotransferase (BCAT) would be canonical targets. "Branched-chain amino acid pathways" is *not* itself a specific molecular target, hence `is_target: false` and `is_incorrect: true`[1][3][4].

Other names

Branched-chain amino acid metabolismBCAA catabolic pathwayBCAA degradation pathway

Reduction or bypass of BCAA accumulation by substituting amino acids without BCAA content (for Maapliv in MSUD)